The design of the software system for the interpretation and guidance of drug locus related to drug treatment_Journal of Biomedical Engineering

Authors：

DING Ruifeng ¹ , XU Xiulin ¹ , QING Tao ² ,  HU Xiufang ¹

1. School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai 200093, P.R.China;
2. School of Life Sciences, Fudan University, Shanghai 200438, P.R.China;

Corresponding?author：

HU Xiufang, Email: huxiufang1965@163.com

Keywords：

pharmacogenomics; precise medication; container virtualization

DOI：

10.7507/1001-5515.201805001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Based on the pharmacogenomics theory, this study developed a software system for interpretation of drug gene loci and guidance on clinical safe medication with the purpose of providing clinical guidance on the safety and effectiveness of drug use through accurate and efficient detection and interpretation of drug gene loci. The system infrastructure was built on a service-oriented architecture (SOA) design and Docker container virtualization approach to achieve a rapid and automatic interpretation of genetic results and best available drugs. The front end was established on HTML5 and JavaScript to realize visualization of analysis results and user interaction. The system was tested and validated to show robust performance which is reliable in clinical use. It will show high impact on the development of pharmacogenomics and clinical practice of patients with personalized medicine.

Citation： DING Ruifeng, XU Xiulin, QING Tao, HU Xiufang. The design of the software system for the interpretation and guidance of drug locus related to drug treatment. Journal of Biomedical Engineering, 2019, 36(4): 657-663. doi: 10.7507/1001-5515.201805001 Copy

1.	Giacomini K M, Yee S W, Ratain M J, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med, 2012, 4(153): ps18.
2.	Wang L, Mcleod H L, Weinshilboum R M. Genomics and drug response. New Engl J Med, 2011, 364(12): 1144-1153.
3.	Roederer M W, McLeod H L. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics, 2010, 11(5): 633-636.
4.	Weinshilboum R M, Wang Liewei. Pharmacogenetics and pharmacogenomics: development, science, and translation. Ann Rev Genom Hum Gen, 2006, 7(7): 223-245.
5.	van der Wouden C H, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther, 2017, 101(3): 341-358.
6.	王濤, 王丹, 董鐸, 等. 美國藥物警戒體系淺析及對我國的啟示. 醫藥導報, 2017, 36(4): 361-365.
7.	張曉丹, 向倩, 胡琨, 等. 藥物基因組學在新藥臨床研究中的應用現狀. 中國臨床藥理學雜志, 2017, 33(23): 2508-2510.
8.	徐冠, 禹建春, 吳昌枝. 基層醫院藥品不良反應的綜合分析與對策. 中醫藥管理雜志, 2018, 26(1): 79-80.
9.	耿春梅, 郭瑞臣. 藥物基因組學在新藥臨床試驗及個體化用藥中的應用. 藥學進展, 2015, 39(11): 803-809.
10.	Wishart D S, Feunang Y D, Guo A C, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46(D1): 1074-1082.
11.	Barbarino J M, Whirl-Carrillo M, Altman R B, et al. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med, 2018, 10(4): e1417.
12.	Lester J, Neyarapally G A, Lipowski E, et al. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf, 2013, 22(3): 302-305.
13.	Ewing B, Hillier L D, Wendl M C, et al. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Research, 1998, 8(3): 175-185.
14.	Sztriha L K, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci, 2005, 229-230(3): 163-169.
15.	Moriyama B, Obeng A O, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther, 2017, 102(1): 45-51.
16.	Mega J L, Hochholzer W, Frelinger A L, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA, 2011, 306(20): 2221-2228.
17.	Shiotani A, Murao T, Fujita Y, et al. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One, 2013, 8(12): e84244.
18.	Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis, 2013, 35(1): 95-99.
19.	王瑋霄, 禚艷麗. 比較阿司匹林與氯吡格雷對腦梗死患者的臨床療效與不良反應. 中國現代藥物應用, 2018, 12(3): 3-5.

1. Giacomini K M, Yee S W, Ratain M J, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med, 2012, 4(153): ps18.
2. Wang L, Mcleod H L, Weinshilboum R M. Genomics and drug response. New Engl J Med, 2011, 364(12): 1144-1153.
3. Roederer M W, McLeod H L. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics, 2010, 11(5): 633-636.
4. Weinshilboum R M, Wang Liewei. Pharmacogenetics and pharmacogenomics: development, science, and translation. Ann Rev Genom Hum Gen, 2006, 7(7): 223-245.
5. van der Wouden C H, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther, 2017, 101(3): 341-358.
6. 王濤, 王丹, 董鐸, 等. 美國藥物警戒體系淺析及對我國的啟示. 醫藥導報, 2017, 36(4): 361-365.
7. 張曉丹, 向倩, 胡琨, 等. 藥物基因組學在新藥臨床研究中的應用現狀. 中國臨床藥理學雜志, 2017, 33(23): 2508-2510.
8. 徐冠, 禹建春, 吳昌枝. 基層醫院藥品不良反應的綜合分析與對策. 中醫藥管理雜志, 2018, 26(1): 79-80.
9. 耿春梅, 郭瑞臣. 藥物基因組學在新藥臨床試驗及個體化用藥中的應用. 藥學進展, 2015, 39(11): 803-809.
10. Wishart D S, Feunang Y D, Guo A C, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46(D1): 1074-1082.
11. Barbarino J M, Whirl-Carrillo M, Altman R B, et al. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med, 2018, 10(4): e1417.
12. Lester J, Neyarapally G A, Lipowski E, et al. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf, 2013, 22(3): 302-305.
13. Ewing B, Hillier L D, Wendl M C, et al. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Research, 1998, 8(3): 175-185.
14. Sztriha L K, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci, 2005, 229-230(3): 163-169.
15. Moriyama B, Obeng A O, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther, 2017, 102(1): 45-51.
16. Mega J L, Hochholzer W, Frelinger A L, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA, 2011, 306(20): 2221-2228.
17. Shiotani A, Murao T, Fujita Y, et al. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One, 2013, 8(12): e84244.
18. Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis, 2013, 35(1): 95-99.
19. 王瑋霄, 禚艷麗. 比較阿司匹林與氯吡格雷對腦梗死患者的臨床療效與不良反應. 中國現代藥物應用, 2018, 12(3): 3-5.

Journal of Biomedical Engineering

The design of the software system for the interpretation and guidance of drug locus related to drug treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content